4.7 Article

Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret

Journal

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 48, Issue 2, Pages 169-178

Publisher

WILEY
DOI: 10.1111/apt.14797

Keywords

-

Funding

  1. Deutsche Forschungsgemeinschaft [DFG SFB841, KFO306]
  2. YAEL Foundation
  3. Helmut and Hannelore Greve Foundation
  4. MRC [G0801588] Funding Source: UKRI

Ask authors/readers for more resources

Background: In patients with primary sclerosing cholangitis follow-up magnetic resonance imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP) is performed by many centres, particularly for the early detection of biliary malignancies and strictures. Clinically meaningful MRI-based definitions of primary sclerosing cholangitis related complications are, however, lacking. Aim: To investigate how primary sclerosing cholangitis experts interpret follow-up MRI/MRCP with a focus on conclusions that may impact clinical decision-making in primary sclerosing cholangitis. Methods: Within the International Primary Sclerosing Cholangitis Study Group, an online survey on 16 real-life primary sclerosing cholangitis cases including clinical and biochemical information as well as a T2-weighted liver MRI/3D-MRCP was conducted. The interpretation of images and subsequent recommendations were assessed using a multiple-choice questionnaire. An inter-rater reliability calculation (Fleiss kappa) was performed and factors potentially affecting the interpretation of magnetic resonance images were analysed using generalised linear mixed-effect models. Results: Forty-four members/associates of the International Primary Sclerosing Cholangitis Study Group (median experience in the care of primary sclerosing cholangitis patients: 14 years) completed the survey. The MRI interpretation significantly varied among the participants. The lowest agreement was found with respect to the indication to perform subsequent endoscopic retrograde cholangiopancreatography (ERCP; =0.12, 95%CI 0.11-0.14). Elevated total bilirubin was the variable with the strongest effect on the rate of suspected dominant strictures, cholangiocarcinoma or ERCP recommendations. Liver cirrhosis did not prevent participants from recommending ERCP. Overall, the survey participants recommendations contrasted the real-life management and outcome. Conclusions: In primary sclerosing cholangitis, the interpretation of follow-up MRI/3D-MRCP significantly varies even among experts and seems to be primarily affected by bilirubin levels. Generally accepted MRI-based definitions of primary sclerosing cholangitis-related complications are urgently needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC

Michael Trauner, Christopher L. Bowlus, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman, Charles Landis, Andrew J. Muir, Andrew Billin, Jun Xu, Xiangyu Liu, Xiaomin Lu, Chuhan Chung, Robert P. Myers, Kris V. Kowdley

Summary: In this 96-week open-label extension study, Cilofexor was found to be safe and effective in improving liver function and biomarkers of cholestasis and cellular injury in patients with PSC.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen-Chieh Chuang, Julie Lin, Wen-Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin

Summary: This study evaluated IL-31 as a potential biomarker for pruritus in clinical trials of cilofexor, an FXR agonist, in patients with cholestatic liver diseases. IL-31 levels were found to be elevated in patients with PSC and PBC and correlated with serum bile acids. The study also showed that cilofexor therapy increased IL-31 levels in patients with NASH.

HEPATOLOGY (2023)

Article Surgery

The impact of perceived donor liver quality on post-transplant outcome

Melisa Dirchwolf, Chiara Becchetti, Susanne Stampf, Christa Haldimann, Franz Immer, Franziska Beyeler, Christian Toso, Philipp Dutkowski, Daniel Candinas, Jean-Francois Dufour, Vanessa Banz

Summary: This study analyzed the impact of perceived liver donor quality on transplant recipient outcomes. It included all deceased liver donors during 2008-2018 in the Swiss Transplant Cohort Study. The results showed that perceived poor-quality liver donors accounted for 19.2% of the total, but this did not significantly affect re-listing or death within the first week and first year post-transplant.

ANZ JOURNAL OF SURGERY (2023)

Article Gastroenterology & Hepatology

Polyp characteristics at screening colonoscopy and post- colonoscopy colorectal cancer mortality: a retrospective cohort study

Jasmin Zessner-Spitzenberg, Lena Jiricka, Elisabeth Waldmann, Lisa -Maria Rockenbauer, Jeremy Cook, Anna Hinterberger, Barbara Majcher, Aleksandra Szymanska, Arno Asaturi, Michael Trauner, Monika Ferlitsch

Summary: A retrospective study with 316,001 individuals revealed that polyps sized 10-20mm and high-grade dysplasia are significantly associated with post-colonoscopy colorectal cancer (PCCRC) mortality. Patients with polyps <10mm and without high-grade dysplasia have significantly lower PCCRC mortality compared to the general population, while those with polyps >10mm or with high-grade dysplasia do not have this advantage.

GASTROINTESTINAL ENDOSCOPY (2023)

Article Infectious Diseases

Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates

David Chromy, David Bauer, Benedikt Simbrunner, Mathias Jachs, Lukas Hartl, Philipp Schwabl, Teresa Binter, Lisa Steininger, Caroline Schwarz, Armin Rieger, Katharina Grabmeier-Pfistershammer, Michael Trauner, Peter Ferenci, Markus Peck-Radosavljevic, Mattias Mandorfer, Thomas Reiberger

Summary: HCV cure rates in Viennese HIV patients increased significantly from 49% in the IFN era to 88-95% in the DAA era. However, MSM-related risk behavior and reinfections have become the key challenges towards HCV elimination in HIV/HCV-coinfected patients.

INFECTIOUS DISEASES (2023)

Article Oncology

Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinomada European multicenter cohort

K. Pomej, L. Balcar, K. Shmanko, S. Welland, V. Himmelsbach, B. Scheiner, A. Mahyera, B. Mozayani, M. Trauner, F. Finkelmeier, A. Weinmann, A. Vogel, M. Pinter

Summary: There is no consensus on the optimal systemic treatment regimen for combined hepatocellular-cholangiocarcinoma (cHCC-CCA) patients. This European multicenter study analyzed the clinical characteristics and outcomes of cHCC-CCA patients, focusing on those receiving palliative systemic therapy, including immune checkpoint inhibitors (ICIs). The study found no significant difference in overall survival, progression-free survival, overall response rate, and disease control rate between patients receiving cytotoxic chemotherapy (CHT) and non-cytotoxic chemotherapy (nCHT).

ESMO OPEN (2023)

Article Gastroenterology & Hepatology

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, Kris Kowdley, John M. Vierling, Cynthia Levy, Andreas E. Kremer, Ehud Zigmond, Pietro Andreone, Stuart C. Gordon, Christopher L. Bowlus, Eric J. Lawitz, Richard J. Aspinall, Daniel S. Pratt, Karina Raikhelson, Maria S. Gonzalez-Huezo, Michael A. Heneghan, Sook-Hyang Jeong, Alma L. Ladron de Guevara, Marlyn J. Mayo, George N. Dalekos, Joost P. H. Drenth, Ewa Janczewska, Barbara A. Leggett, Frederik Nevens, Victor Vargas, Eli Zuckerman, Christophe Corpechot, Eduardo Fassio, Holger Hinrichsen, Pietro Invernizzi, Palak J. Trivedi, Lisa Forman, David E. J. Jones, Stephen D. Ryder, Mark G. Swain, Alexandra Steinberg, Pol F. Boudes, Yun-Jung Choi, Charles A. McWherter

Summary: This study evaluated the efficacy and safety of seladelpar in patients with primary biliary cholangitis who had inadequate response or intolerance to ursodeoxycholic acid. The results showed that seladelpar significantly improved liver biochemistry and pruritus in these patients, and it was well tolerated.

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes

Grazia Pennisi, Marco Enea, Vincenzo Falco, Guruprasad P. Aithal, Naaventhan Palaniyappan, Yusuf Yilmaz, Jerome Boursier, Christophe Cassinotto, Victor de Ledinghen, Wah Kheong Chan, Sanjiv Mahadeva, Peter Eddowes, Philip Newsome, Thomas Karlas, Johannes Wiegand, Vincent Wai-Sun Wong, Joern M. Schattenberg, Christian Labenz, Won Kim, Myoung Seok Lee, Monica Lupsor-Platon, Jeremy F. L. Cobbold, Jian-Gao Fan, Feng Shen, Katharina Staufer, Michael Trauner, Rudolf Stauber, Atsushi Nakajima, Masato Yoneda, Elisabetta Bugianesi, Ramy Younes, Silvia Gaia, Ming-Hua Zheng, Calogero Camma, Quentin M. Anstee, Ferenc E. Mozes, Michael Pavlides, Salvatore Petta

Summary: This study evaluated the diagnostic accuracy of simple, noninvasive tests (NITs) in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). The results showed that liver stiffness measurement (LSM) and AGILE 3+ were better at determining advanced fibrosis compared to serum tests. The evaluation of diagnostic methods for NAFLD with T2D is clinically significant.

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, Quentin M. Anstee, Juan Pablo Arab, Marco Arrese, Ramon Bataller, Ulrich Beuers, Jerome Boursier, Elisabetta Bugianesi, Christopher D. Byrne, Graciela E. Castro Narro, Abhijit Chowdhury, Helena Cortez-Pinto, Donna R. Cryer, Kenneth Cusi, Mohamed El-Kassas, Samuel Klein, Wayne Eskridge, Jiangao Fan, Samer Gawrieh, Cynthia D. Guy, Stephen A. Harrison, Seung Up Kim, Bart G. Koot, Marko Korenjak, Kris V. Kowdley, Florence Lacaille, Rohit Loomba, Robert Mitchell-Thain, Timothy R. Morgan, Elisabeth E. Powell, Michael Roden, Manuel Romero-Gomez, Marcelo Silva, Shivaram Prasad Singh, Silvia C. Sookoian, C. Wendy Spearman, Dina Tiniakos, Luca Valenti, Miriam B. Vos, Vincent Wai-Sun Wong, Stavra Xanthakos, Yusuf Yilmaz, Zobair Younossi, Ansley Hobbs, Marcela Villota-Rivas, Philip N. Newsome

Summary: This study aimed to determine if there was a need to change the nomenclature and definition of NAFLD and NASH. Through a Delphi process involving content experts and patient advocates, a consensus was reached to replace NAFLD with metabolic dysfunction-associated steatotic liver disease (MetALD) and modify the diagnostic criteria. The new nomenclature and criteria are widely supported, nonstigmatizing, and can improve awareness and patient identification.

HEPATOLOGY (2023)

Review Gastroenterology & Hepatology

Intermittent fasting-the future treatment in NASH patients?

Iulia Minciuna, Suchira Gallage, Mathias Heikenwalder, Shira Zelber-Sagi, Jean-Francois Dufour

Summary: NASH, a chronic liver disease that can progress to end-stage liver disease and HCC, can be effectively treated with intermittent fasting, which not only induces weight loss but also reduces inflammation and oxidative stress.

HEPATOLOGY (2023)

Article Multidisciplinary Sciences

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients

Lorenz Balcar, David Bauer, Katharina Pomej, Tobias Meischl, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Bernhard Scheiner, Matthias Pinter

Summary: Immunotherapy is the new standard of care for hepatocellular carcinoma, but there is a need for biomarkers that predict treatment response and survival. This study suggests that the relative change in IgG after ICI treatment can serve as a negative prognostic marker in patients with HCC.

PLOS ONE (2023)

Article Oncology

Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines

Al B. Benson, Michael I. D'Angelica, Thomas Abrams, Daniel E. Abbott, Aijaz Ahmed, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, David Binder, Mitesh Borad, Christopher Bowlus, Daniel Brown, Adam Burgoyne, Jason Castellanos, Prabhleen Chahal, Jordan Cloyd, Anne M. Covey, Evan S. Glazer, William G. Hawkins, Renuka Iyer, Rojymon Jacob, Lawrence Jennings, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Sean Ronnekleiv-Kelly, Vaibhav Sahai, Gagandeep Singh, Stacey Stein, Anita Turk, Jean-Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole McMillian, Ryan Schonfeld, Cindy Hochstetler

Summary: In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into two separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The Biliary Tract Cancers guidelines provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. A multidisciplinary panel of experts meets regularly to review new data and therapies.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2023)

Article Gastroenterology & Hepatology

Autoimmune liver diseases and diabetes: A propensity score matched analysis and a proportional meta-analysis

Anne-Sofie H. Jensen, Marie Winther-Sorensen, Johan Burisch, Annika Bergquist, Henriette Ytting, Lise L. Gluud, Nicolai J. Wewer Albrechtsen

Summary: Patients with autoimmune liver diseases have a significantly increased risk of diabetes. Increased awareness of diabetes risk in patients with autoimmune liver diseases is warranted.

LIVER INTERNATIONAL (2023)

Review Radiology, Nuclear Medicine & Medical Imaging

Primary sclerosing cholangitis: review for radiologists

Matthew A. Morgan, Rachita Khot, Karthik M. Sundaram, Daniel R. Ludwig, Rashmi T. Nair, Pardeep K. Mittal, Dhakshina M. Ganeshan, Sudhakar K. Venkatesh

Summary: Primary sclerosing cholangitis is a chronic disease that affects the bile ducts, leading to various complications. Imaging plays a crucial role in diagnosis and treatment.

ABDOMINAL RADIOLOGY (2023)

Review Radiology, Nuclear Medicine & Medical Imaging

MR elastography in primary sclerosing cholangitis: a pictorial review

Christopher L. Welle, Patrick J. Navin, Michael C. Olson, Safa Hoodeshenas, Michael S. Torbenson, Sudhakar K. Venkatesh

Summary: Primary sclerosing cholangitis is a chronic liver disease without effective medical treatment, and liver fibrosis is a crucial factor in patient outcome. Magnetic resonance elastography is an accurate non-invasive method for assessing liver fibrosis and is particularly important in evaluating PSC patients.

ABDOMINAL RADIOLOGY (2023)

No Data Available